

**Overall objectives of HCC studies presented at 2013 AASLD, November 1<sup>st</sup>- 4<sup>th</sup>**

Abstract No.	Question
2141 2142 2105 2089 2124 2116 2098 2168 2154 2176	<ul style="list-style-type: none"> <li>➤ Variation in demographics, clinicpathological, different staging systems, treatment response following different treatment modalities, prognosis and survival with               <ul style="list-style-type: none"> <li>✓ HCV ± HIV patients</li> <li>✓ HBV ± HIV patients</li> <li>✓ HCV ± cirrhotic patients</li> <li>✓ HBV ± cirrhotic patients</li> <li>✓ Diabetics</li> <li>✓ Smokers</li> <li>✓ Obesity</li> <li>✓ Physical exercise</li> <li>✓ Nonalcoholic Fatty liver</li> </ul> </li> <li>➤ Difference in staging and prognosis between patients with Reactive versus nonreactive Hepatitis virus</li> <li>➤ Safety of sorafenib with different disease etiology</li> </ul>
2102 2188 2189	Correlation between aging and HCC development in HCV and HBV patients
2170 2184 2191	Impact of tumor differentiation on treatment response and survival
2145	Drawbacks of bile ducts invasion on treatment outcome
2155	Baseline AFP in correlation with PVT and vascular invasion
2198	Predictors of mortality after local therapy
2185	Changing in liver function with repeated local therapy
2110	ART scoring for assessment of patients candidate for 2 <sup>nd</sup> TACE
2164	<ul style="list-style-type: none"> <li>➤ MELD score alone versus with electrotypes including ferritin</li> <li>➤ Serum ferritin as a predictor marker for early recurrence</li> </ul>
2151	<ul style="list-style-type: none"> <li>➤ Trends of HCV HCC over time</li> <li>➤ Trends of HBV HCC over time</li> <li>➤ Trends of HIV HCC over time</li> </ul>
2118	Difference in HCC patients survival before after the era of MELD
2162	One versus multiple local approaches result in less tumor recurrence
2169 2178	Relation between sarcopenia detected by CT and recurrence rate
2146	Impact of age on different treatment modalities outcome
2094	Impact of Post progression survival on overall survival for patients treated with systemic therapy

2095	What is more predictor for survival in patients treated with serial local therapy: is it the best response or the initial response
249	Changing demographics and clinicpathological features of HCC patients with time
2196	Changing in tumor stain on contrast enhanced CT as a predictor for sorafenib efficacy
2150	MESIAH Score in comparison with other scoring systems for evaluation of HCC pt. survival
2161	Validating the heterogeneity of BCLC-B patients by the used of new subgrouping system
2163 1542 1565	MRI versus PET-CT in denovo HCC pt.: Cost benefit ratio
2192 2093 1566	Gadolinium ethoxybenzyl diethylenetriamine pancreatic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging a predictor for hepatocellular carcinoma:
2134	Low Serum Vit. D as a predictor for advanced disease and early recurrence or progression
2158	Des-gamma-carboxy prothrombin versus AFP for diagnosis of HCC
2126 2135 2156 2107 2167 2207 2197	<ul style="list-style-type: none"> <li>➤ Clinical Outcome between Sorafenib alone versus with different local therapy approaches in met. HCC</li> <li>➤ Clinical outcome between locally advanced HCC patients treated with Sorafenib alone versus with different local therapy</li> <li>➤ Sequential versus concurrent sorafenib with local therapy in unresectable HCC</li> <li>➤ Patients progressed on sorafenib: whether to continue or not</li> <li>➤ Safety and efficacy of Sorafenib in relation to age</li> <li>➤ Safety and tolerability of sorafenib for Child Pugh B &amp; C</li> </ul>
2111	<ul style="list-style-type: none"> <li>➤ Epithelial–mesenchymal transition markers expressed in circulating tumor cells in HCC pts.</li> <li>➤ Epithelial–mesenchymal transition as a tissue tumor marker in HCC pts.</li> </ul>
2153 2129	Protein induced by Vit-K absence II (PIVK-II) versus AFP as a diagnostic and prognostic markers of HCC
2092	Vasohibin-1 as a marker for angiogenesis in HCC pt.
2200	Correlation between Ribosomal protein e.g S23 expressed in HCC tissue biopsy and treatment outcome
2088	HCV/HBV genome in relation to HCC development, treatment response and MELD Score
2183	Hexokinase II immunoexpression in relation to different HCC tumor differentiation
2160	Hypovascular versus hypervascular HCC: demographics, clinicpathological, different staging systems, treatment response following different treatment modalities, prognosis and survival.
252 2121	<ul style="list-style-type: none"> <li>➤ Impact of PNPLA3 on development of HCC</li> </ul>

	➤ PNPLA3 expressed or not: difference in demographics, clinicopathological, different staging systems, treatment response following different treatment modalities, prognosis and survival
2147	Serum N-Glycan as a marker for early detection of HCC
2122	M-CSF expression in liver tissue as an angiogenesis inducer and its correlation with clinicopathological, different staging systems, treatment response
2081	Molecular predictors of micro-invasion in HCC tissue specimens
2174	Serial measurement of VEGF after sorafenib as a predictor for prognosis and survival
2204	Morbidity and mortality following different local therapy approaches
2209	Impact of PS in early HCC BCLC stage on survival
2120	➤ Impact of multidisciplinary decision versus one man decision on HCC survival rate
2177	
2083	
2201	FIB-4 index as a predictor for early tumor recurrence
2190	Impact of AFP on treatment decision and patients outcome
2103	
2137	Correlation Baseline Serum glycan and patients outcome in those treated with sorafenib
2182	HCC progenitor cell markers “CK19 and epithelial cell adhesion molecule EpCAM” in correlation with clinicopathological, treatment response and prognosis
2143	Clinicopathological prognostic factors of tumor recurrence
2193	Prognostic scoring for predicting post-TACE outcome??????
2148	Correlation between serum VEGF and AFP for diagnosis of patients
2079	Clinicopathological predictors for tumor progression and overall survival
2099	Possibility of tumor seedling with HCC tumor biopsy
2100	
2138	Serial measurement of IGF1 as a predictor for prognosis, early recurrence and survival
2132	Sorafenib versus systemic Cth for recurrent HCC
2144	Role of EMT as a promoting markers for prognosis and metastasis of HCC patients.
2114	Role of serum exosomes for early detection of tumor recurrences
2128	Sorafenib with or without vit K and treatment outcome